An FDA rebuke of televised comments made by Aegerion’s CEO—which led the company to air a TV commercial correcting the statements—was prompted by complaints from a government drug reviewer, according to emails viewed by The Wall Street Journal.
via WSJ.com: US Business http://ift.tt/1E0Rgjw
via WSJ.com: US Business http://ift.tt/1E0Rgjw
Nessun commento:
Posta un commento